Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients.

Next Previous
Trial Profile

Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients.

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use

Most Recent Events

  • 12 Aug 2012 Recruitment is ongoing at the Far Eastern Memorial Hospital, according to ClinicalTrials.gov (NCT01657487).
  • 12 Aug 2012 Recruitment is ongoing at the Far Eastern Memorial Hospital, according to ClinicalTrials.gov (NCT01657487).
  • 06 Aug 2012 Biomarkers information updated

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top